Tag:
Vivus
Latest Headlines
Latest Headlines
After going it alone, Vivus finally open to Big Pharma sales partnership
Vivus' announcement that the company is looking to partner with Big Pharma for marketing help to get its new weight-loss drug, Qsymia, off the ground apparently encouraged investors. Shares rose 9.7% to $13.21, the biggest one-day increase since Dec. 17, Bloomberg reported.
Arena pulls app for weight-loss drug Belviq in EU
Arena Pharmaceuticals has decided to take its drug application and go home. The drugmaker Friday said it was giving up for now on breaking through the European wall of resistance to its weight-loss drug Belviq. The company, which got FDA approval last year, yanked its application with little explanation.
Vivus clears one of many hurdles for new weight drug
The FDA has agreed to take down one of the big hurdles hampering U.S. sales of Vivus' newly approved weight drug Qsymia, but plenty more remain.
Vivus revs up new Qsymia sales plan after FDA removes a roadblock
The FDA has agreed to take down one of the big hurdles hampering U.S. sales of Vivus' newly approved weight drug Qsymia, but plenty more remain.
Vivus investor says FDA move on Qsymia isn't enough
At least one Vivus shareholder isn't convinced that loosening FDA restrictions on a new obesity pill will fuel sales in any significant way. First Manhattan, which owns a 9.1% stake in the drugmaker, said that modifications to Qsymia's risk-management plan are "necessary"--but they're "not sufficient" for its success.
Vivus hopes weight-loss app will fatten up Qsymia sales
Weight-loss apps have become popular, so why not a weight-loss app for a weight-loss drug? Qsymia maker Vivus figures it is worth a try.
Vivus dials up iPhone app to boost Qsymia sales
Weight-loss apps have become popular, so why not a weight-loss app for a weight-loss drug? Qsymia maker Vivus figures it is worth a try.
Vivus hopes weight-loss app will fatten up Qsymia sales
Weight-loss apps have become popular, so why not a weight-loss app for a weight-loss drug? Qsymia maker Vivus figures it is worth a try.
Vivus investor plots board takeover to rally Qsymia sales
Vivus may rue the day that it decided to go solo on marketing its new obesity drug, Qsymia. Despite some fanfare around its U.S. approval, the drug's sales have foundered. Vivus is trying to move Qsymia off the rocks, but so far, the market is unconvinced.
With Qsymia sales sputtering, Vivus shares take a dive
The advent of new obesity drugs was supposed to be a watershed moment. No new fat-fighting pills had been approved in years, and some one in three Americans are obese. But so far, physicians haven't been quick to pull out their prescription pads.
